Hongxi Wu

发表

In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature.

Jian-qiang Yu, Guang-Jiang Shi, Yan Li, 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Xi Xu, Jingwei Jiang, Wanli Ye, 2022, Acta pharmaceutica Sinica. B.

Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway

Yundong He, L. Birnbaumer, J. Bian, 2018, Oncogene.

Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy

L. Birnbaumer, Wanli Ye, Zhen Chen, 2022, Hepatology.

Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.

Xi Xu, Qianming Du, Zhiyu Li, 2020, European journal of medicinal chemistry.

Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.

J. Bian, Qingyi Zhu, Hongxi Wu, 2017, Cancer letters.

Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment

Yushi Ding, Hongxi Wu, Yong Yang, 2021, Theranostics.

Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells

Qiuhua Cao, Hongxi Wu, Yong Yang, 2018, Clinical Cancer Research.

Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

J. Bian, Jin-Rong Zhou, Wanli Ye, 2020, Cancer Research.

Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy

L. Birnbaumer, Wanli Ye, Zhen Chen, 2022, Hepatology.

SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.

Ying Tang, Rui Sun, Hongxi Wu, 2017, European journal of pharmacology.

Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.

Jie Ren, Zhiyu Li, Jinlei Bian, 2021, European journal of medicinal chemistry.

2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.

Jiaping Ni, Ying Li, Haoying Zhang, 2021, Pharmacological research.